TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02791737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete individualized exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Complete individualized exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00959478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Tool & Carbon Monoxide Alarm
Description: Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
Study: NCT02565680

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Xyzall 5mg during 5 days + placebo 40mg during 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Xyzall 5mg during 5 days + prednisone 40mg during 4 days
Study: NCT00437567

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galacto-oligosaccharide (GOS)
Description: Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar quantity of sterile water to be added to milk
Study: NCT02566889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
Study: NCT02570620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography of the cervix
Study: NCT01863914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
Study: NCT03759548

Intervention type: OTHER
Intervention: Assessment of nutritional status
Description: Observational study. Assessment of nutritional status.

Intervention type: OTHER
Intervention: Assessment of nutritional status
Description: Observational study. Assessment of nutritional status.
Study: NCT04181619

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coffeeberry beverage
Description: One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage prior to exercise session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Comparator beverage
Description: One 300 ml still beverage, color and flavor matched to experimental beverage prior to exercise session
Study: NCT01417637

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
Study: NCT00370552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
Description: Ixabepilone,16 mg/m\^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg
Description: Ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m\^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Description: Paclitaxel, 90 mg/m\^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Study: NCT00948272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vero Rabies Vaccine - Serum Free
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified inactivated rabies vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03981107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Compression Only CPR (CO-CPR) performed by trained bystanders after instructions from dispatchers
Description: Instructions by dispatcher to bystander to provide CPR with chest-compressions only~The instructions from the dispatcher in interventional arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions only~* Push hard on the chest with a pace of 100/minute without interruptions for rescue breathing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR (S-CPR) performed by trained bystanders after instructions from dispatchers
Description: Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a ration of 30:2~The Instructions from the dispatcher in the control arm include:~* An ambulance is dispatched and is on it´s way to you~* Do CPR with chest compressions and rescue breathing~* Push hard on the chest 30 times and give 2 rescue breaths. The pace of the compressions should be 100/minute.
Study: NCT03597295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).
Study: NCT00005095

Intervention type: OTHER
Intervention: Ca-125
Description: Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.

Intervention type: OTHER
Intervention: screening questionnaire administration
Description: Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.

Intervention type: PROCEDURE
Intervention: Surgery
Description: Subjects will be assessed for high risk factors.
Study: NCT00634868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qray light therapy device
Description: The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Qray light therapy device-Sham
Description: non curative light- the device emits the same broad light, but with very low intensity
Study: NCT03327844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RET using antibiotics (Ciprofloxacin and Metronidazole)
Description: RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RET using non-setting Calcium Hydroxide
Description: First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
Study: NCT04386382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting flapless technique using interchangeable guide followed by implant placement
Description: An informed consent is taken from all the patients~I. Presurgical phase:~1. Proper dental and medical history.~2. Scaling and oral hygiene measurements.~3. Clinical examination.~4. Radiographic examination. Clinical bucco-lingual measurements was done using calipers to ensure the patients would meet our initial inclusion criteria prior to further investigations.~III. Fabrication of interchangeable surgical guide stent from primary impression:~1. Optical scanning of the dental casts was done using Ceramill map 400~2. surgical stent was designed using Mimics Innovation Suite 19 ™ software.~3. Series of creating and designing special 3D virtual guide slits and boxes that can accommodate and precisely fit the tools used for the ridge splitting technique.~All patients will be operated under local anesthesia, stent was placed on ridge and adapted well after disinfection osteotomy was done using piezotome splitting tips Implant-insertion was started immediately
Study: NCT01144611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bIAP bolus and 8h infusion
Description: intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bolus and 8h infusion
Description: intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
Study: NCT00794768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days
Study: NCT04200820

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trampoline
Description: During trampoline training that participants undergo constant change of vestibular stimulation. This triggers deep proprioception as well as other sensory inputs. This trigger might affect strength, body stability, muscle coordinative responses, joint movement amplitudes and spatial integration
Study: NCT02154867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal transplantation
Description: Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fecal transplant
Description: Fecal transplantation with own feces
Study: NCT03896698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound Stimulation
Description: TUS activate the brain cells
Study: NCT02736552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 for 6 months
Description: 6 months S-1 after D2 resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 for 1 year
Description: 1 year S-1 after D2 resection
Study: NCT00894621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
Study: NCT04520620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox 40 MG in 0.4 mL Prefilled Syringe
Description: Patients with a high thrombotic risk:~In patients with a BMI included between \< 30 kg/m² and \> 30 kg/m² without added thrombotic risk factor:~* Enoxaparin 40 milligrams, (4,000 IU) twice daily subcutaneously (SC) for the entire duration of the intensive care hospitalization~* if weight \> 120 kg, enoxaparin 60 milligrams (6000 IU) twice daily subcutaneously for the entire duration of the intensive care hospitalization~Patients with a very high thrombotic risk:~In patients with a BMI \> 30 kg/m2 with added thrombotic risk factor (active cancer, recent personal history of thromboembolic event), or if iterative or unusual catheter thromboses, or if marked inflammatory syndrome and/or hypercoagulability (e.g. fibrinogen \> 8 g/L or D-Dimer \> 3 μg/ml or 3000 ng/ml)~\* Enoxaparin sodium curative at a dose of 100 IU/kg/12h subcutaneously (SC) not to exceed a dose of 100 mg/12 hours
Study: NCT01246193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Therapy
Description: Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily
Study: NCT00816062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Talent Abdominal Stent Graft
Description: The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
Study: NCT00633217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg
Description: treatment drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
Description: treatment drug
Study: NCT00517517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
Description: Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
Description: Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
Study: NCT00755560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole 10 - 15 mg/kg/day BID for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 15 days
Study: NCT03080207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP method
Description: It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Level Laser
Description: Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy
Description: Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
Study: NCT00903357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast first, then placebo
Description: Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast first, then placebo
Description: Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo first, then Montelukast
Description: Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo first, then Montelukast
Description: Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks.
Study: NCT04520620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound of the lower limbs
Description: A 4-point compression ultrasound will be performed. In case of suspicion, an angiologist will perform to check the absence of legs thrombosis.
Study: NCT04405089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Active Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training
Description: Cognitive training concurrent with 2 milliamperes (mAmps) of anodal stimulation applied to the right prefrontal cortex for total of 26 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device: Sham Transcranial Direct Current Stimulation (tDCS) coupled with cognitive training
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).